Virginia Cancer Institute
Virginia Cancer Institute
 
 

At Virginia Cancer Institute, we provide treatment, support, and follow-up care for people with cancer and blood disorders. Our purpose is to provide our patients with care that includes efficiency and compassion. The Virginia Cancer Institute is committed to offering care in an atmosphere of professionalism, encouragement, and understanding. Virginia Cancer Institute serves you by offering the best treatment plans, answering questions to your satisfaction, and respecting your informed decisions.

Virginia Cancer Institute's mission is to deliver high-quality, comprehensive medical care while maintaining our patients' quality of life. We offer a team approach for your cancer treatment by involving experts in medical oncology, hematology, chemotherapy, and clinical research.

The goal of our Web site is to:

  • Provide information about our programs, special services, physicians, and other health care professionals.
  • Help you understand your diagnosis and treatment choices.
  • Keep you focused on your quality of life.

We strive to promote respect, understanding, honesty, compassion, integrity, teamwork, individuality, and confidentiality at all times. We will remain committed to our purpose by remaining innovative and continuously increasing our awareness of technological advancements and the latest treatment methods. The physicians and staff continue to strive to remain dedicated to this mission.

Virginia Cancer Institute is dedicated to understanding the causes, prevention, and detection of cancer and to improving the quality of life for individuals living with cancer. Virginia Cancer Institute strives to be in the forefront of modern cancer care through the thoughtful introduction of promising new methods of treatment, the active participation in clinical research, the recruitment, development and education of highly trained oncology personnel, and the use of state-of-the art medical equipment.

 
 
Latest Cancer News

PET Scans Often Impact Physicians’ Treatment Decisions (05/08/2008)
A recently published study finds that results from positron emission tomography (PET) scans often influence a physician’s intended management plan among elderly patients diagnosed with cancer. Full details of the study were published in the Journal of Clinical Oncology.

Nexavar® Shows Promise for the Treatment of Advanced Melanoma (05/08/2008)
Researchers from the United States have recently reported that, among patients with advanced melanoma, the addition to chemotherapy of the drug Nexavar® (sorafenib) improved progression-free survival. Full details of the study were published in the Journal of Clinical Oncology.

Worse Prognosis for “Bulky” Disease Diffuse Large B-Cell Lymphoma (05/08/2008)
Young patients with diffuse large-B-cell lymphoma (DLBCL) with cancerous masses that are 10.0 centimeters or greater in diameter are considered to have “bulky” disease and have a worse prognosis than those with smaller masses. These findings were published in Lancet Oncology.